Skip to main content

Advertisement

SpringerLink
Log in

Urinary Biomarkers and Benign Prostatic Hyperplasia

  • Voiding Dysfunction Evaluation (B Brucker and B Peyronnet, Section Editors)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Benign prostatic hyperplasia (BPH) is a common age-related benign proliferation of the epithelial and stromal components of the prostate. Symptomatic BPH is associated with the progressive development of lower urinary tract symptoms (LUTS), which left untreated can deteriorate over time and lead to acute urinary retention, urinary incontinence, recurrent urinary tract infections, and/or obstructive uropathy.

Recent Findings

Surgical or medical treatment that correct bladder outlet obstruction from BPH in patients generally resolves voiding symptoms and reduces the urine levels of neurotrophins. Histological analysis of the prostate biopsies obtained from BPH patients enrolled in large clinical studies supported the role of prostatic inflammation in BPH/LUTS. However, the invasive nature of biopsy motivates the research in alternative biofluids for the discovery of biomarkers to influence the clinical management of BPH. We recently reported that urinary levels of chemokines are associated with the evidence of prostatic inflammation and measures of obesity in BPH patients.

Summary

Detection of inflammatory mediators in urine of BPH patients has the potential to displace biopsy for discriminating BPH-related pathologies, identify risk of progressive disease, and personalize the management of BPH-related LUTS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. • Yoo S, Oh S, Park J, Cho SY, Cho MC, Jeong H, et al. The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men. BJU Int. 2018;123(1):140–8. https://doi.org/10.1111/bju.14528. Important epidemiological study demonstrating the influence of obesity on BPH.

    Article  CAS  PubMed  Google Scholar 

  2. • Oelke M, Wagg A, Takita Y, Buttner H, Viktrup L. Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged ≥75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. BJU Int. 2017;119(5):793–803. https://doi.org/10.1111/bju.13744. Important study on the medical treatment of storage symptoms in BPH patients.

    Article  CAS  PubMed  Google Scholar 

  3. • Vella M, Abrate A, Costanzo A, D'Amato F, Tarantino ML, Simonato A. Predictive variables of spontaneous micturition recovery after acute urinary retention in men with benign prostatic enlargement: an observational prospective study. Lower urinary tract symptoms. 2018. Doi:https://doi.org/10.1111/luts.12241. Important study identifying the predictors of treatment response.

  4. •• Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, Moreira DM. Chronic prostate inflammation is associated with severity and progression of benign prostatic hyperplasia, lower urinary tract symptoms and risk of acute urinary retention. J Urol. 2016;196(5):1493–8. https://doi.org/10.1016/j.juro.2016.06.090. Important study implicating the role of prostatic inflammation in incidence of acute urinary retention and BPH/LUTS.

    Article  PubMed  Google Scholar 

  5. Torkko KC, Wilson RS, Smith EE, Kusek JW, van Bokhoven A, Lucia MS. Prostate biopsy markers of inflammation are associated with risk of clinical progression of benign prostatic hyperplasia: findings from the MTOPS study. J Urol. 2015;194(2):454–61. https://doi.org/10.1016/j.juro.2015.03.103.

    Article  PubMed  Google Scholar 

  6. • Matsukawa Y, Takai S, Majima T, Funahashi Y, Kato M, Yamamoto T, et al. Two-year follow up of silodosin on lower urinary tract functions and symptoms in patients with benign prostatic hyperplasia based on prostate size: a prospective investigation using urodynamics. Ther Adv Urol. 2018;10(9):263–72. https://doi.org/10.1177/1756287218783646. Important study on the influence of prostate size on treatment outcomes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. •• Young MJ, Elmussareh M, Morrison T, Wilson JR. The changing practice of transurethral resection of the prostate. Ann R Coll Surg Engl. 2018;100(4):326–9. https://doi.org/10.1308/rcsann.2018.0054. Important study demonstrating the benefits and shortcomings of TURP.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2008;179(5 Suppl):S75–80. https://doi.org/10.1016/j.juro.2008.03.141.

    Article  PubMed  Google Scholar 

  9. McNeal J, Noldus J. Limitations of transition zone needle biopsy findings in the prediction of transition zone cancer and tissue composition of benign nodular hyperplasia. Urology. 1996;48(5):751–6. https://doi.org/10.1016/S0090-4295(96)00254-3.

    Article  CAS  PubMed  Google Scholar 

  10. Descazeaud A, Rubin MA, Hofer M, Setlur S, Nikolaief N, Vacherot F, et al. BPH gene expression profile associated to prostate gland volume. Diagn Mol Pathol : the American journal of surgical pathology, part B. 2008;17(4):207–13. https://doi.org/10.1097/PDM.0b013e31816f6352.

    Article  CAS  Google Scholar 

  11. Robert G, Descazeaud A, Nicolaiew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate. 2009;69(16):1774–80. https://doi.org/10.1002/pros.21027.

    Article  PubMed  PubMed Central  Google Scholar 

  12. • Hashimoto M, Shimizu N, Sugimoto K, Hongoh S, Minami T, Nozawa M, et al. Efficacy of adding dutasteride to alpha-blocker therapy treated benign prostatic hyperplasia patients with small volume prostate (<30 mL). Lower Urin Tract Symp. 2017;9(3):157–60. https://doi.org/10.1111/luts.12127. Important study on the influence of prostate size on treatment decision making.

    Article  CAS  Google Scholar 

  13. Lin-Tsai O, Clark PE, Miller NL, Fowke JH, Hameed O, Hayward SW, et al. Surgical intervention for symptomatic benign prostatic hyperplasia is correlated with expression of the AP-1 transcription factor network. Prostate. 2014;74(6):669–79. https://doi.org/10.1002/pros.22785.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Mullins C, Lucia MS, Hayward SW, Lee JY, Levitt JM, Lin VK, et al. A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA consortium. J Urol. 2008;179(4):1243–56. https://doi.org/10.1016/j.juro.2007.11.049.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Gumus BH, Nese N, Gunduz MI, Kandiloglu AR, Ceylan Y, Buyuksu C. Does asymptomatic inflammation increase PSA? A histopathological study comparing benign and malignant tissue biopsy specimens. Int Urol Nephrol. 2004;36(4):549–53.

    Article  CAS  Google Scholar 

  16. Macoska JA. Chemokines and BPH/LUTS. Differentiation. 2011;82(4–5):253–60. https://doi.org/10.1016/j.diff.2011.04.003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100. https://doi.org/10.1016/j.mcna.2010.08.013.

    Article  PubMed  Google Scholar 

  18. Liu L, Li Q, Han P, Li X, Zeng H, Zhu Y, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia. Urology. 2009;74(2):340–4. https://doi.org/10.1016/j.urology.2009.02.064.

    Article  PubMed  Google Scholar 

  19. Fujita K, Ewing CM, Getzenberg RH, Parsons JK, Isaacs WB, Pavlovich CP. Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia. Prostate. 2010;70(5):473–81. https://doi.org/10.1002/pros.21081.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Desireddi NV, Campbell PL, Stern JA, Sobkoviak R, Chuai S, Shahrara S, et al. Monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha as possible biomarkers for the chronic pelvic pain syndrome. J Urol. 2008;179(5):1857–61; discussion 61-2. https://doi.org/10.1016/j.juro.2008.01.028.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hu H, Zhang W, Liu X, Wang H, Fang Z, Liang C, et al. Nerve growth factor levels are associated with overactive bladder symptoms and long-term treatment outcome after transurethral resection of the prostate in patients with benign prostatic hyperplasia. J Urol. 2018;200(3):620–5. https://doi.org/10.1016/j.juro.2018.03.130.

    Article  CAS  PubMed  Google Scholar 

  22. •• Perez-Rambla C, Puchades-Carrasco L, Garcia-Flores M, Rubio-Briones J, Lopez-Guerrero JA, Pineda-Lucena A. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics. 2017;13(5):52. https://doi.org/10.1007/s11306-017-1194-y. Important study on the urine metabolomics approach in BPH.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. • Wang LW, Li JL, Yu Y, Xiao RH, Huang HW, Kuang RR, et al. Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia. J Huazhong Univ Sci Technol Med Sci. 2017;37(4):531–5. https://doi.org/10.1007/s11596-017-1768-y. Important study linking urinary BDNF to LUTS.

    Article  CAS  PubMed  Google Scholar 

  24. Tanaka T, Minami A, Tashiro K, Yoshida N, Tohda A, Yamakoshi Y, et al. Urine miR-21-5p as a potential biomarker for predicting effectiveness of tadalafil in benign prostatic hyperplasia. Future Sci OA. 2018;4(6):FSO304. https://doi.org/10.4155/fsoa-2018-0012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. • Tyagi P, Motley SS, Koyama T, Kashyap M, Gingrich J, Yoshimura N, et al. Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. Prostate. 2018;78(1):17–24. https://doi.org/10.1002/pros.23439. Important study linking urinary sIL-1ra to obesity in BPH aptients.

    Article  CAS  PubMed  Google Scholar 

  26. • Tyagi P, Tyagi V, Qu X, Chuang YC, Kuo HC, Chancellor M, et al. Chemokines in urine noninvasively discriminate OAB from UTI. Am J Physiol Ren Physiol. 2016;311(3):F548–54. https://doi.org/10.1152/ajprenal.00213.2016. Important study illustrating differences in urinary chemokine levels in UTI and non-infective LUTS.

    Article  CAS  Google Scholar 

  27. • Tyagi P, Killinger K, McLennan G, Jayabalan N, Chancellor M, Peters KM. Urine chemokine levels correlate with treatment response to phosphodiesterase 4 inhibitor in prostatitis. World J Clin Urol. 2017;6(1):18–26. Important study demonstrating the use of urinary chemokines to indicate treatment response.

    Article  CAS  Google Scholar 

  28. Cho MC, Song WH, Park J, Cho SY, Jeong H, Oh SJ, et al. Long-term outcomes of laser prostatectomy for storage symptoms: comparison of serial 5-year followup data between high performance system photoselective vaporization and holmium laser enucleation of the prostate. J Urol. 2018;199(6):1591–9. https://doi.org/10.1016/j.juro.2018.01.022.

    Article  PubMed  Google Scholar 

  29. Barbosa J, Reis ST, Nunes M, Ferreira YA, Leite KR, Nahas WC, et al. The obstructed bladder: expression of collagen, matrix metalloproteinases, muscarinic receptors, and angiogenic and neurotrophic factors in patients with benign prostatic hyperplasia. Urology. 2017;106:167–72. https://doi.org/10.1016/j.urology.2017.05.010.

    Article  PubMed  Google Scholar 

  30. • Cho MC, Park J, Kim JK, Cho SY, Jeong H, Oh SJ, et al. Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? A serial 3-year follow-up study. Neurourol Urodyn. 2018;37(1):407–16. https://doi.org/10.1002/nau.23317. Important study on surgical therapy for obstruction.

    Article  CAS  PubMed  Google Scholar 

  31. • Kashyap MP, Pore SK, de Groat WC, Chermansky CJ, Yoshimura N, Tyagi P. BDNF overexpression in the bladder induces neuronal changes to mediate bladder overactivity. Am J Physiol Ren Physiol. 2018;315(1):F45–56. https://doi.org/10.1152/ajprenal.00386.2017. Important study demonstrating the mechanistic link between urine BDNF levels and LUTS.

    Article  CAS  Google Scholar 

  32. • Antunes-Lopes T, Vasconcelos A, Costa D, Charrua A, Neves J, Silva J, et al. The impact of chronic pelvic ischemia on LUTS and urinary levels of neuroinflammatory, inflammatory, and oxidative stress markers in elderly men: a case-control study. Urology. 2018;123:230–4. https://doi.org/10.1016/j.urology.2018.09.004. Important study demonstrating urine levels of different biomarkers.

    Article  PubMed  Google Scholar 

  33. • Ito H, Wang D, Zha X, Inamura S, Seki M, Taga M, et al. Castration increases PGE2 release from the bladder epithelium in male rats. Life Sci. 2018;193:252–6. https://doi.org/10.1016/j.lfs.2017.10.037. Important study demonstrating the changes in bladder wall in response to castration.

    Article  CAS  PubMed  Google Scholar 

  34. Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, et al. Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH. Prostate Cancer Prostatic Dis. 2009;12(2):152–9. https://doi.org/10.1038/pcan.2008.49.

    Article  CAS  PubMed  Google Scholar 

  35. Di Carlo E, Magnasco S, D'Antuono T, Tenaglia R, Sorrentino C. The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21. Prostate. 2007;67(10):1070–80. https://doi.org/10.1002/pros.20604.

    Article  CAS  PubMed  Google Scholar 

  36. Steiner GE, Stix U, Handisurya A, Willheim M, Haitel A, Reithmayr F, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Investig. 2003;83(8):1131–46.

    Article  CAS  Google Scholar 

  37. Nickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001;87(9):797–805.

    Article  CAS  Google Scholar 

  38. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60(1):106–17. https://doi.org/10.1016/j.eururo.2011.03.055.

    Article  CAS  PubMed  Google Scholar 

  39. Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, et al. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Investig. 1992;66(1):96–107.

    CAS  PubMed  Google Scholar 

  40. •• Kulac I, Gumuskaya B, Drake CG, Gonzalez B, Arnold KB, Goodman PJ, et al. Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial. Prostate. 2016;76(15):1399–408. https://doi.org/10.1002/pros.23224. Important study demonstrating the effect on LUTS from inflammation in different zones of prostate.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Roehrborn CG. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int. 2008;101(Suppl 3):17–21. https://doi.org/10.1111/j.1464-410X.2008.07497.x.

    Article  PubMed  Google Scholar 

  42. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, et al. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. Cancer. 2014;120(2):190–6. https://doi.org/10.1002/cncr.28349.

    Article  CAS  PubMed  Google Scholar 

  43. Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology. 2011;78(3):641–6. https://doi.org/10.1016/j.urology.2011.03.063.

    Article  PubMed  Google Scholar 

  44. Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS. Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol. 2011;186(4):1313–8. https://doi.org/10.1016/j.juro.2011.05.071.

    Article  CAS  PubMed  Google Scholar 

  45. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol. 2006;164(8):760–8. https://doi.org/10.1093/aje/kwj258.

    Article  PubMed  Google Scholar 

  46. Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51(5):1202–16. https://doi.org/10.1016/j.eururo.2006.12.011.

    Article  CAS  PubMed  Google Scholar 

  47. Collin M, Linge HM, Bjartell A, Giwercman A, Malm J, Egesten A. Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract. J Reprod Immunol. 2008;79(1):37–43. https://doi.org/10.1016/j.jri.2008.08.003.

    Article  CAS  PubMed  Google Scholar 

  48. Linge HM, Collin M, Giwercman A, Malm J, Bjartell A, Egesten A. The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma. J Interf Cytokine Res. 2008;28(3):191–6. https://doi.org/10.1089/jir.2007.0100.

    Article  CAS  Google Scholar 

  49. Ao M, Franco OE, Park D, Raman D, Williams K, Hayward SW. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res. 2007;67(9):4244–53. https://doi.org/10.1158/0008-5472.CAN-06-3946.

    Article  CAS  PubMed  Google Scholar 

  50. Perez de Lema G, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol. 2001;12(7):1369–82.

    CAS  PubMed  Google Scholar 

  51. Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182(7):4056–64. https://doi.org/10.4049/jimmunol.0801875.

    Article  CAS  PubMed  Google Scholar 

  52. Penna G, Mondaini N, Amuchastegui S, Degli Innocenti S, Carini M, Giubilei G, et al. Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Eur Urol. 2007;51(2):524–33 discussion 33.

    Article  CAS  Google Scholar 

  53. Mortier A, Van Damme J, Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther. 2008;120(2):197–217. https://doi.org/10.1016/j.pharmthera.2008.08.006.

    Article  CAS  PubMed  Google Scholar 

  54. Macoska JA, Begley LA, Dunn RL, Siddiqui J, Wei JT, Sarma AV. Pilot and feasibility study of serum chemokines as markers to distinguish prostatic disease in men with low total serum PSA. Prostate. 2008;68(4):442–52. https://doi.org/10.1002/pros.20717.

    Article  CAS  PubMed  Google Scholar 

  55. Konig JE, Senge T, Allhoff EP, Konig W. Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer. Prostate. 2004;58(2):121–9. https://doi.org/10.1002/pros.10317.

    Article  CAS  PubMed  Google Scholar 

  56. Agarwal M, He C, Siddiqui J, Wei JT, Macoska JA. CCL11 (eotaxin-1): a new diagnostic serum marker for prostate cancer. Prostate. 2013;73(6):573–81. https://doi.org/10.1002/pros.22597.

    Article  CAS  PubMed  Google Scholar 

  57. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A. 2002;99(11):7598–603. https://doi.org/10.1073/pnas.112191399.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Gharaee-Kermani M, Kasina S, Moore BB, Thomas D, Mehra R, Macoska JA. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One. 2012;7(11):e49278. https://doi.org/10.1371/journal.pone.0049278.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Tyagi P, Motley SS, Kashyap M, Pore S, Gingrich J, Wang Z, et al. Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. Int Urol Nephrol. 2015;47(7):1051–8. https://doi.org/10.1007/s11255-015-0992-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Spary LK, Salimu J, Webber JP, Clayton A, Mason MD, Tabi Z. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 PD-L1 phenotype in prostate cancer. Oncoimmunology. 2014;3(9):e955331. https://doi.org/10.4161/21624011.2014.955331.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Fan Y, Hu S, Liu J, Xiao F, Li X, Yu W, et al. Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion. Mediat Inflamm. 2014;2014:397815–9. https://doi.org/10.1155/2014/397815.

    Article  CAS  Google Scholar 

  62. Song L, Zhu Y, Han P, Chen N, Lin D, Lai J, et al. A retrospective study: correlation of histologic inflammation in biopsy specimens of Chinese men undergoing surgery for benign prostatic hyperplasia with serum prostate-specific antigen. Urology. 2011;77(3):688–92. https://doi.org/10.1016/j.urology.2010.07.493.

    Article  PubMed  Google Scholar 

  63. Morote J, Lopez M, Encabo G, de Torres IM. Effect of inflammation and benign prostatic enlargement on total and percent free serum prostatic specific antigen. Eur Urol. 2000;37(5):537–40.

    Article  CAS  Google Scholar 

  64. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol. 2010;42(3):629–35. https://doi.org/10.1007/s11255-009-9647-5.

    Article  PubMed  Google Scholar 

  65. Motamedinia P, Scott AN, Bate KL, Sadeghi N, Salazar G, Shapiro E, et al. Urine exosomes for non-invasive assessment of gene expression and mutations of prostate cancer. PLoS One. 2016;11(5):e0154507. https://doi.org/10.1371/journal.pone.0154507.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Bolduc S, Lacombe L, Naud A, Gregoire M, Fradet Y, Tremblay RR. Urinary PSA: A potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL. Can Urol Assoc J = Journal de l’Association des urologues du Canada. 2007;1(4):377–81.

    Article  Google Scholar 

  67. Shibuya S, Xia Z, Sugimoto M, Ueda N, Haba R, Kakehi Y. The phytotherapeutic agent, eviprostat, suppresses stromal proliferation and inflammation even after establishment of nonbacterial prostatitis in the rat prostate. Urology. 2014;83(3):528–34. https://doi.org/10.1016/j.urology.2013.11.033.

    Article  PubMed  Google Scholar 

  68. Jia X, Chen J, Sun S, Yang W, Yang S, Shah P, et al. Detection of aggressive prostate cancer associated glycoproteins in urine using glycoproteomics and mass spectrometry. Proteomics. 2016;16(23):2989–96. https://doi.org/10.1002/pmic.201500506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Haraldsson B, Nystrom J, Deen WM. Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451–87. https://doi.org/10.1152/physrev.00055.2006.

    Article  CAS  PubMed  Google Scholar 

  70. Wada N, Matsumoto S, Kita M, Hashizume K, Kakizaki H. Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride. Int J Urol. 2014;21(12):1258–62. https://doi.org/10.1111/iju.12570.

    Article  CAS  PubMed  Google Scholar 

  71. Corcoran AT, Yoshimura N, Tyagi V, Jacobs B, Leng W, Tyagi P. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–6. https://doi.org/10.1007/s00345-012-0852-y.

    Article  CAS  PubMed  Google Scholar 

  72. Otoni A, Teixeira AL, Voieta I, Antunes CM, Costa Melo VL, Drummond SC, et al. Chemokine profile in the sera and urine of patients with schistosomal glomerulopathy. Am J Trop Med Hyg. 2014;90(1):48–53. https://doi.org/10.4269/ajtmh.13-0270.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Kupelian V, Rosen RC, Roehrborn CG, Tyagi P, Chancellor MB, McKinlay JB. Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) survey. BJU Int. 2012;110(3):401–7. https://doi.org/10.1111/j.1464-410X.2011.10769.x.

    Article  CAS  PubMed  Google Scholar 

  74. Tyagi P, Chancellor M, Kupelian V, Araujo A, Rosen R, McKinlay J. Obesity, inflammation and overactive bladder: preliminary results from a pilot study of serum leptin and mcp-1 levels in men and women with and without OAB symptoms. J Urol. 2011;185(4, Supplement):e462–e3. https://doi.org/10.1016/j.juro.2011.02.763.

    Article  Google Scholar 

  75. Irani J, Goujon JM, Ragni E, Peyrat L, Hubert J, Saint F, et al. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy. Pathol Multi Center Stud Group Urol. 1999;54(3):467–72.

    CAS  Google Scholar 

  76. Kashyap M, Pore S, Wang Z, Gingrich J, Yoshimura N, Tyagi P. Inflammasomes are important mediators of prostatic inflammation associated with BPH. J Inflamm (Lond). 2015;12:37. https://doi.org/10.1186/s12950-015-0082-3.

    Article  CAS  Google Scholar 

  77. Tyagi P, Kashyap M, Gingrich J, Wang Z, Yoshimura N. Mediators of prostatic inflammation: simultaneous multiplex analysis of urine and serum specimens. J Urol. 2017;197(4):161.

    Article  Google Scholar 

  78. • Fowke JH, Koyama T, Fadare O, Clark PE. Does inflammation mediate the obesity and BPH relationship? An epidemiologic analysis of body composition and inflammatory markers in blood, urine, and prostate tissue, and the relationship with prostate enlargement and lower urinary tract symptoms. PLoS One. 2016;11(6):e0156918. https://doi.org/10.1371/journal.pone.0156918. Important study on serum analysis in BPH patients.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Nobles C, Bertone-Johnson ER, Ronnenberg AG, Faraj JM, Zagarins S, Takashima-Uebelhoer BB, et al. Correlation of urine and plasma cytokine levels among reproductive-aged women. Eur J Clin Investig. 2015;45(5):460–5. https://doi.org/10.1111/eci.12428.

    Article  CAS  Google Scholar 

  80. Vignozzi L, Rastrelli G, Corona G, Gacci M, Forti G, Maggi M. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Investig. 2014;37(4):313–22. https://doi.org/10.1007/s40618-014-0051-3.

    Article  CAS  Google Scholar 

  81. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168(2):599–604.

    Article  CAS  Google Scholar 

  82. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002;13(4–5):323–40.

    Article  CAS  Google Scholar 

  83. Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009;30(4):698–705. https://doi.org/10.1093/carcin/bgp043.

    Article  CAS  PubMed  Google Scholar 

  84. Konwar R, Gara R, Singh M, Singh V, Chattopadhyay N, Bid HK. Association of interleukin-4 and interleukin-1 receptor antagonist gene polymorphisms and risk of benign prostatic hyperplasia. Urology. 2008;71(5):868–72. https://doi.org/10.1016/j.urology.2007.12.072.

    Article  PubMed  Google Scholar 

  85. Yadav DK, Tripathi AK, Gupta D, Shukla S, Singh AK, Kumar A, et al. Interleukin-1B (IL-1B-31 and IL-1B-511) and interleukin-1 receptor antagonist (IL-1Ra) gene polymorphisms in primary immune thrombocytopenia. Blood Res. 2017;52(4):264–9. https://doi.org/10.5045/br.2017.52.4.264.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Rokita H, Kosz-Vnenchak M, Stalinska K, Stachura J. Interleukin 1 receptor antagonist localization exclusively in non-parenchymal cells of the mouse liver. Cytokine. 1997;9(4):249–53. https://doi.org/10.1006/cyto.1996.0161.

    Article  CAS  PubMed  Google Scholar 

  87. Giri D, Ittmann M. Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. Am J Pathol. 2000;157(1):249–55.

    Article  CAS  Google Scholar 

  88. Vital P, Castro P, Tsang S, Ittmann M. The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. Am J Pathol. 2014;184(3):721–31. https://doi.org/10.1016/j.ajpath.2013.11.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002;87(3):1184–8. https://doi.org/10.1210/jcem.87.3.8351.

    Article  CAS  PubMed  Google Scholar 

  90. Charles BA, Doumatey A, Huang H, Zhou J, Chen G, Shriner D, et al. The roles of IL-6, IL-10, and IL-1RA in obesity and insulin resistance in African-Americans. J Clin Endocrinol Metab. 2011;96(12):E2018–22. https://doi.org/10.1210/jc.2011-1497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Bresnihan B, Cobby M. Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. Rheumatology (Oxford). 2003;42(Suppl 2):ii22–8. https://doi.org/10.1093/rheumatology/keg329.

    Article  Google Scholar 

  92. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 1998;159(4):1247–50.

    Article  CAS  Google Scholar 

  93. Silva-Ramos M, Silva I, Oliveira JC, Correia-de-Sa P. Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia. Prostate. 2016;76(15):1353–63. https://doi.org/10.1002/pros.23207.

    Article  CAS  PubMed  Google Scholar 

  94. Schauer IG, Ressler SJ, Tuxhorn JA, Dang TD, Rowley DR. Elevated epithelial expression of interleukin-8 correlates with myofibroblast reactive stroma in benign prostatic hyperplasia. Urology. 2008;72(1):205–13. https://doi.org/10.1016/j.urology.2007.11.083.

    Article  PubMed  PubMed Central  Google Scholar 

  95. Fontenete S, Silva J, Teixeira AL, Ribeiro R, Bastos E, Pina F, et al. Controversies in using urine samples for prostate cancer detection: PSA and PCA3 expression analysis. Int Braz J Urol : official journal of the Brazilian Society of Urology. 2011;37(6):719–26.

    Article  CAS  Google Scholar 

  96. Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals. 2009;14(4):235–43. https://doi.org/10.1080/13547500902807306.

    Article  CAS  Google Scholar 

  97. Pejcic T, Hadzi-Djokic J, Markovic B, Dragicevic D, Glisic B, Lalic N, et al. Urinary PSA level and relative tumor volume after prostate biopsy. Acta Chirurgica Iugoslavica. 2009;56(2):17–21.

    Article  CAS  Google Scholar 

  98. Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL Jr, et al. Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology. 1999;53(1):139–47.

    Article  CAS  Google Scholar 

  99. Reynard JM, Yang Q, Donovan JL, Peters TJ, Schafer W, de la Rosette JJ, et al. The ICS-‘BPH’ study: uroflowmetry, lower urinary tract symptoms and bladder outlet obstruction. Br J Urol. 1998;82(5):619–23.

    Article  CAS  Google Scholar 

  100. Wu T, Fu Y, Brekken D, Yan M, Zhou XJ, Vanarsa K, et al. Urine proteome scans uncover total urinary protease, prostaglandin D synthase, serum amyloid P, and superoxide dismutase as potential markers of lupus nephritis. J Immunol. 2010;184(4):2183–93. https://doi.org/10.4049/jimmunol.0900292.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Kamata Y, Kimura U, Matsuda H, Tengara S, Kamo A, Umehara Y, et al. Relationships among plasma granzyme B level, pruritus and dermatitis in patients with atopic dermatitis. J Dermatol Sci. 2016;84:266–71. https://doi.org/10.1016/j.jdermsci.2016.09.009.

    Article  CAS  PubMed  Google Scholar 

  102. Hung SF, Chung SD, Kuo HC. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS One. 2014;9(1):e85588. https://doi.org/10.1371/journal.pone.0085588.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Jacobs BL, Smaldone MC, Tyagi V, Philips BJ, Jackman SV, Leng WW, et al. Increased nerve growth factor in neurogenic overactive bladder and interstitial cystitis patients. Can J Urol. 2010;17(1):4989–94.

    PubMed  Google Scholar 

  104. Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–8. https://doi.org/10.1016/j.juro.2012.01.034.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was partly supported by NIDDK grant U54 DK112079.

Author information

Authors and Affiliations

  1. Department of Urology, University of Pittsburgh, Pittsburgh, PA, USA

    Pradeep Tyagi, Zhou Wang & Naoki Yoshimura

  2. Department of Urology, University of Pittsburgh School of Medicine, Suite 700 Kaufmann Medical Building, 3471 Fifth Avenue, Pittsburgh, PA, 15213, USA

    Pradeep Tyagi

Authors
  1. Pradeep Tyagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhou Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoki Yoshimura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pradeep Tyagi.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Voiding Dysfunction Evaluation

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tyagi, P., Wang, Z. & Yoshimura, N. Urinary Biomarkers and Benign Prostatic Hyperplasia. Curr Bladder Dysfunct Rep 14, 31–40 (2019). https://doi.org/10.1007/s11884-019-00504-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-019-00504-z

Keywords

Search

Navigation